Tuspel100 ml

Tuspel is a combination cough/cold product indicated for the temporary symptomatic relief of cough and chest congestion associated with the common cold, minor upper respiratory tract infections, or minor throat and bronchial irritation.

• Established/approved use: Temporary relief of cough due to minor throat and bronchial irritation (dextromethorphan, an antitussive), together with loosening and thinning of bronchial mucus secretions to make coughs more productive (guaifenesin, an expectorant).
• Adjunct/symptomatic use: Menthol provides a soothing, cooling sensation in the throat and mild local relief of throat irritation associated with cough and cold.
• Tuspel is intended for short-term, symptomatic use only and does not treat the underlying cause of cough (e.g., infection, allergy, asthma).

This combination is not indicated for chronic cough associated with smoking, chronic bronchitis, emphysema, or asthma, or for cough accompanied by excessive phlegm, unless directed by a physician.

Each dose of Guaifenesin + Dextromethorphan + Menthol typically contains three active ingredients (strengths vary by brand/dosage form and should be confirmed on the specific product label):

• Guaifenesin – an expectorant
• Dextromethorphan (usually as dextromethorphan hydrobromide) – a cough suppressant (antitussive)
• Menthol – a soothing/cooling agent

Guaifenesin + Dextromethorphan + Menthol is commonly available as an oral syrup/liquid for adults and children above the recommended minimum age.

Tuspel is a fixed-dose combination medicine used for the symptomatic relief of cough and chest congestion. It combines an expectorant (guaifenesin), a centrally-acting cough suppressant (dextromethorphan), and a topical soothing agent (menthol) in a single formulation.

Tuspel is intended to relieve the discomfort of cough associated with colds and minor throat/bronchial irritation while also helping to loosen mucus so that any cough that does occur is more productive. It provides temporary, symptomatic relief and is not a cure for the underlying condition causing the cough.

Tuspel belongs to the therapeutic class of cough and cold preparations, specifically combination expectorant–antitussive–soothing agent preparations used for upper respiratory symptom relief.

Guaifenesin + Dextromethorphan + Menthol combines three agents with complementary mechanisms of action:

• Guaifenesin is an expectorant that is thought to increase the volume and reduce the viscosity of respiratory tract secretions by stimulating the flow of bronchial fluid, making cough more productive and easier to clear.
• Dextromethorphan is a centrally-acting antitussive that suppresses the cough reflex by acting on the cough center in the medulla of the brain. It is chemically related to opioids but has no significant analgesic or addictive properties at recommended doses and does not cause respiratory depression at therapeutic doses.
• Menthol acts locally on mucous membranes of the throat, producing a cooling sensation and mild local anesthetic effect that reduces the urge to cough and soothes throat irritation.

Together, these actions in Guaifenesin + Dextromethorphan + Menthol reduce the frequency and severity of non-productive cough while facilitating clearance of respiratory secretions.

Tuspel is administered orally as a liquid/syrup. Use the measuring device provided with the product to ensure accurate dosing. Shake well before use if indicated on the label. Do not use with any other medicine containing dextromethorphan or guaifenesin without consulting a physician or pharmacist, to avoid additive toxicity.

Monoamine oxidase inhibitors (MAOIs): Concurrent use of Tuspel with an MAOI, or use within 14 days of stopping an MAOI, is contraindicated. The combination of dextromethorphan and MAOIs can precipitate serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes) and hypertensive crisis. See Contraindications.

Other serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, triptans, other serotonergic agents): Concomitant use with dextromethorphan may increase the risk of serotonin syndrome; use with caution and medical supervision.

Other dextromethorphan- or guaifenesin-containing products: Avoid taking Tuspel together with other cough/cold products containing dextromethorphan or guaifenesin, as this can lead to additive toxicity/overdose.

CNS depressants (alcohol, sedatives, opioids): May increase drowsiness/sedation when taken with Tuspel; avoid concurrent use or use with caution.

CYP2D6 inhibitors (e.g., quinidine, certain SSRIs): May increase dextromethorphan plasma levels, raising the risk of dextromethorphan-related adverse effects.

Most side effects of Tuspel are mild and transient. Reported adverse effects include:

• Dizziness or drowsiness
• Nausea, vomiting, or other gastrointestinal disturbance (e.g., stomach upset)
• Nervousness, restlessness, anxiety, or irritability
• Headache
• Rash or mild allergic skin reactions (uncommon)

Rarely, high doses of dextromethorphan can cause more serious effects such as confusion, hallucinations, or (in overdose or with interacting drugs) serotonin syndrome. Seek medical attention for any severe or persistent reaction. See Overdose Effects and Precautions and Warnings.

Pregnancy: Data on the use of Tuspel in human pregnancy are limited. As with most cough/cold combination products, Tuspel should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Consult a physician before use during pregnancy.

Lactation: It is not well established whether the components of Tuspel pass into breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted before use by breastfeeding mothers.

Use Tuspel with caution and consult a physician before use in the following situations:

• Cough that persists for more than 7 days, recurs, or is accompanied by high fever, rash, or persistent headache — these may indicate a condition requiring medical evaluation rather than continued self-treatment with Tuspel.
• Chronic cough associated with smoking, chronic bronchitis, emphysema, or asthma, or cough accompanied by excessive phlegm (mucus) — a physician should determine the cause before use.
• Patients with a history of depression or other psychiatric conditions being treated with MAOIs — see Contraindications and Interactions.
• Avoid taking Tuspel together with other products containing dextromethorphan or guaifenesin, or with alcohol or other CNS depressants, due to the risk of additive sedation or toxicity.
• Use with caution in patients with persistent or chronic cough, or underlying respiratory disease, without first consulting a physician.

Keep out of reach of children. Discontinue use and seek medical advice if symptoms worsen or new symptoms occur.

Overdose of Tuspel, particularly of the dextromethorphan component, may cause nausea, vomiting, drowsiness, confusion, blurred vision, ataxia (loss of coordination), agitation, hallucinations, and, in severe cases, respiratory depression, seizures, or serotonin syndrome (especially if combined with other serotonergic drugs).

In case of suspected overdose, seek immediate medical attention or contact a poison control center right away. Do not attempt to treat overdose at home. Bring the product container/packaging when seeking medical help.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Tuspel and other cough/cold combination products are not recommended for children under 4 to 6 years of age due to the risk of serious side effects, and must never be given to children under 2 years of age. For children 6 to under 12 years, use only the specific pediatric dose under adult supervision. Safety and efficacy in children under 6 years have not been established.

Geriatric Use

No specific dose adjustment is generally required in elderly patients, but they may be more sensitive to the sedative or anticholinergic-like effects; use with caution, particularly in patients with respiratory disease or those taking multiple medications.

Renal/Hepatic Impairment

Specific dose adjustment data for Tuspel in renal or hepatic impairment are not well established; use with caution and under medical supervision in patients with significant renal or hepatic disease.

Tuspel should be used for the shortest duration needed to relieve symptoms, generally not exceeding 7 days of self-treatment. If cough persists beyond 7 days, recurs, or is accompanied by fever, rash, or persistent headache, stop use and consult a physician, as this may indicate an underlying condition requiring further evaluation.

Expectorant + Antitussive (cough suppressant) + Topical soothing/cooling agent (combination cough and cold preparation).

Guaifenesin + Dextromethorphan + Menthol works through three complementary mechanisms: guaifenesin increases respiratory tract fluid secretion to thin and loosen mucus, making cough more productive; dextromethorphan suppresses the cough reflex by acting centrally on the cough center in the brainstem; and menthol provides a local cooling and mild anesthetic effect on the throat mucosa, reducing irritation and the urge to cough.

C

Tuspel is not recommended for children under 4 to 6 years of age due to the risk of serious side effects associated with cough and cold combination products in young children, and must not be given to children under 2 years of age under any circumstances. For children 6 to under 12 years, use only the pediatric dose specified, under the guidance of a caregiver or physician. Safety and efficacy in children below 6 years have not been established. Always use an accurate measuring device for pediatric dosing.